Healthcare / Medical DevicesNasdaqCM
$0.58
-0.03 (-5.41%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-4.1M · quality 49.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$12M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-219.4%
↓Gross Margin
79.7%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
+20.3%
FCF CAGR
—
FCF margin
-1675.6%
FCF / Net income
0.61x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $301647.0 · net income $-8.2M · FCF $-5.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | $301647.00 | $301647.00 | $168721.00 | $110748.00 | $1.3M | $144065.00 |
| Net Income | $-8.2M | $-8.2M | $-7.6M | $-4.6M | $-1.7M | $-6.1M |
| EBITDA | $-8.4M | $-8.4M | $-7.7M | $-5.7M | $-1.8M | — |
| EPS | — | — | -0.83 | -0.63 | -0.30 | — |
| Gross Margin | 79.7% | 79.7% | 78.3% | 76.8% | 72.5% | 85.1% |
| Operating Margin | -2781.7% | -2781.7% | -4596.1% | -5143.5% | -138.7% | -4177.7% |
| Net Margin | -2725.8% | -2725.8% | -4508.7% | -4197.6% | -128.5% | -4218.9% |
| Balance Sheet | ||||||
| Debt/Equity | — | — | — | 0.00 | 0.14 | — |
| Current Ratio | 4.07 | 4.07 | — | — | — | — |
| Cash Flow | ||||||
| Free Cash Flow | $-5.1M | $-5.1M | $-4.1M | $-3.9M | $-2.2M | — |
| Returns | ||||||
| ROE | -219.4% | -219.4% | -206.9% | -145.0% | -31.0% | 361.4% |
| Valuation | ||||||
| P/B | 2.95 | 2.95 | 7.67 | 0.89 | 0.77 | — |
| Growth & Yield | ||||||
| Revenue Growth | 78.8% | 78.8% | 52.3% | -91.6% | — | — |
| EPS Growth | — | — | -31.7% | -110.0% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-51.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.83 → n/d
Residual
-51.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.